Evaluation of vaccine "Sputnik V” immunogenicity and reactogenicity when it is used in military personnel

Abstract

The article presents the results of a study of the immunogenicity and reactogenicity of the vaccine Gam-COVID-Vac (Sputnik V) when used in military personnel undergoing military service on conscription. From 300 military personnel consistently vaccinated with one and two components of Gam-COVID-Vac at the intervals of 21 days, blood serum was obtained and examined three times: before vaccination, and 30 and 60 days after the introduction of the first component of the vaccine. In the blood serums, the content of Class G antibodies to the SARS-CoV-2 was determined by the method of solid-phase enzyme immunoassay. After immunization with the Gam-COVID-Vac vaccine, the average geometric titer of Class G antibodies to SARS-CoV-2 -in the blood serum of a military personnel obtained during the second and third examinations (5.02 log² and 5.67 log²) increased by 2.4 and 2.7 times, respectively (p < 0.05), compared to the same indicator before the vaccination (2.11 log²). Total of 30 days after the introduction of the first component of the vaccine (Nine days after the introduction of the second component of the vaccine), Class G antibodies to the new coronavirus SARS-CoV-2 were detected in the 86.7% of military personnel, and after 60 days — in 92% of vaccinated. Studies have revealed moderate reactogenicity of the vaccine. Moreover, the proportion of postvaccination reactions in the first 3–5 days after the introduction of the second component of the vaccine was less after the introduction of the first component of the vaccine. So, if after the introduction of the first component of the vaccine, an increase in body temperature > 37 °C was observed in 20% of military personnel, then after the introduction of the second component only in 9%, and the share of local reactions decreased from 9−4%. There have been no cases of serious adverse events after immunization of military personnel with the Gam-COVID-Vac vaccine.

Keywords

coronavirus / vaccination / conscripts / Gam-COVID-Vac (Sputnik V) / Class G antibodies / immunogenicity / reactogenicity / post-vaccination reactions

References

[1] Briko NI, Kagramanyan IN, Nikiforov VV, et al. Pandemic COVID-19. Prevention measures in the russian federation. Epidemiology and Vaccinal Prevention. 2020;2:4–12. (In Russ.). DOI: 10.31631/2073-3046-2020-l9-2-4-12

[2] Брико Н.И., Каграманян И.Н., Никифоров В.В., и др. Пандемия COVID-19. Меры борьбы с ее распространением в Российской Федерации // Эпидемиология и вакцинопрофилактика. 2020. Т. 19, № 2. С. 4–12. DOI: 10.31631/2073-3046-2020-l9-2-4-12

[3] Kutyrev VV, Popova AYu, Smolenskij VYu, et al. Epidemiological Features of New Coronavirus Infection (COVID-19). Communication 1: Modes of Implementation of Preventive and Anti-Epidemic Measures. Problems of Particularly Dangerous Infections. 2020;(1): 6–13. (In Russ.). DOI: 10.21055/0370-1069-2020-1-6-13

[4] Кутырев В.В., Попова А.Ю., Смоленский В.Ю., и др. Эпидемиологические особенности новой коронавирусной инфекции (COVID-19). Сообщение 1: Модели реализации профилактических и противоэпидемических мероприятий // Проблемы особо опасных инфекций. 2020. № 1. С. 6–13. DOI: 10.21055/0370-1069-2020-1-6-13

[5] Kryukov EV, Cherkashin DV, Reutskij IA, et al. Differentiated approach to the implementation of preventive and anti-epidemic measures among military personnel based on the COVID-19 disease risk assessment scale. Infectious Diseases: News, Views, Education. 2021;10(2): 31–38. (In Russ.). DOI:10.33029/2305-3496-2021-10-2-31-38

[6] Крюков Е.В., Черкашин Д.В., Реутский И.А., и др. Дифференцированный подход к проведению профилактических и противоэпидемических мероприятий среди военнослужащих на основе шкалы оценки рисков заболевания COVID-19 // Инфекционные болезни: новости, мнения, обучение. 2021. Т. 10, № 2. С. 31–38. DOI: 10.33029/2305-3496-2021-10-2-31-38

[7] Minnullin TI, Stepanov AV, Chepur SV, et al. Immunological aspects of SARS-CoV-2 coronavirus damage. Bulletin of the Russian Military Medical Academy. 2021;23(2):187–198. (In Russ.). DOI: 10.17816/brmma72051

[8] Миннуллин Т.И., Степанов А.В., Чепур С.В., и др. Иммунологические аспекты поражения коронавирусом SARS-CoV-2 // Вестник Российской военно-медицинской академии. 2021. Т. 23, № 2. C. 187–198. DOI: 10.17816/brmma72051

[9] Gumilevskiy BYu, Moskalev AV, Gumilevskaya OP, et al. Features of immunopathogenesis of a new coronavirus infection. Bulletin of the Russian Military Medical Academy. 2021;23(1):187–198. DOI: 10.17816/brmma63654

[10] Гумилевский Б.Ю., Москалев А.В., Гумилевская О.П., и др. Особенности иммунопатогенеза новой коронавирусной инфекции // Вестник Российской военно-медицинской академии. 2021. Т. 23, № 1. C. 187–198. DOI: 10.17816/brmma63654

[11] Trishkin DV, Kryukov EV, Saluhov VV, et al. A prospective multicenter randomized study state of humoral immunity after a new coronavirus infection (COVID-19) of a mild or asymptomatic course. Vestnik RAMN. 2021;76(4):361–367. (In Russ.). DOI: 10.15690/vramn1582

[12] Тришкин Д.В., Крюков Е.В., Салухов В.В., и др. Особенности формирования и продолжительность сохранения нейтрализующих антител к S-белку SARS-CoV-2 у лиц, перенесших новую коронавирусную инфекцию (COVID-19) легкого или бессимптомного течения // Вестник РАМН. 2021. Т. 76, № 4. С. 361–367. DOI: 10.15690/vramn1582

[13] Romashova YuE, Vil'yaninov VN, Bel'gesov NV, Kaleko SP. Screening of potential donors for immunoglobulins M and G to new coronavirus infection. Bulletin of the Russian Military Medical Academy. 2021;23(3):49–54. (In Russ.). DOI: 10.17816/brmma64965

[14] Ромашова Ю.Е., Вильянинов В.Н., Бельгесов Н.В., Калеко С.П. Обследование потенциальных доноров на наличие иммуноглобулинов M и G к новой коронавирусной инфекции // Вестник Российской военно-медицинской академии. 2021. Т. 23, № 3. С. 49–54. DOI: 10.17816/brmma64965

[15] Kuzin AA, Lancov EV, Yumanov AP, et al. View of Military Epidemiologists on the Problem of Global Spread of a New Coronavirus Infection. Epidemiology and Vaccinal Prevention. 2021;20(3):53–59. (In Russ.). DOI: 10.31631/2073-3046-2021-20-3-53-59

[16] Кузин А.А., Ланцов Е.В., Юманов А.П., и др. Взгляд военных эпидемиологов на проблему борьбы с новой коронавирусной инфекцией COVID-19 // Эпидемиология и вакцинопрофилактика. 2021. Т. 20, № 3 С. 53–59. DOI: 10.31631/2073-3046-2021-20-3-53-59

[17] Logunov DYu, Dolzhikova I, Shcheblyakov D, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681. DOI: 10.1016/S0140-6736(21)00234-8

[18] Logunov D.Yu., Dolzhikova I., Shcheblyakov D., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia // Lancet. 2021. Vol. 397. No. 10275. P. 671–681. DOI: 10.1016/S0140-6736(21)00234-8

RIGHTS & PERMISSIONS

Zhogolev S.D., Gorenchuk A.N., Kuzin A.A., Kulikov P.V., Zhogolev K.D., Apchel V.Y., Sergeev T.S., Lantsov E.V., Artebyakin S.V., Zharkov D.A.